Partner Content Partner Content The need for a blueprint emergency plan to avoid a HPAPI cri... HPAPI Safety Strategies
Partner Content Partner Content Registration opens for SMi’s 3rd Annual Ophthalmic Drugs Con... Insights into Ophthalmology
Events Partner Content Ophthalmic Drugs Conference SMi Group are pleased to present the 3rd Annual Ophthalmic Drugs Conference and Focus Day, taking place on the 18th-20th November 2019 in London, UK.
Partner Content Partner Content Insights into HPAPI Containment and Banding Strategies HPAPI USA Updates
Events Partner Content Highly Potent Active Pharmaceutical Ingredients USA (HPAPI) ... HPAPI Strategies
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
